Ligand Pharmaceuticals Inc
LGND191.240USD
-0.070-0.04%
Handelsschluss 11/03, 16:00（ET）Kurse um 15 Minuten verzögert
3.71BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Ligand Pharmaceuticals Inc Unternehmen
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.
Ligand Pharmaceuticals Inc Informationen
BörsenkürzelLGND
Name des UnternehmensLigand Pharmaceuticals Inc
IPO-datumNov 18, 1992
CEOMr. Todd C. Davis
Anzahl der mitarbeiter68
WertpapierartOrdinary Share
GeschäftsjahresendeNov 18
Addresse555 Heritage Drive, Suite 200
StadtJUPITER
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl33458
Telefon18585507500
Websitehttps://www.ligand.com/
BörsenkürzelLGND
IPO-datumNov 18, 1992
CEOMr. Todd C. Davis
Führungskräfte von Ligand Pharmaceuticals Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jason M. Aryeh
Mr. Jason M. Aryeh
Independent Director
Independent Director
127.16K
-7.29%
Dr. John W. Kozarich ,Ph.D.
Dr. John W. Kozarich ,Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
43.90K
-1.05%
Dr. Stephen L. Sabba, M.D.
Dr. Stephen L. Sabba, M.D.
Independent Director
Independent Director
35.05K
+3.57%
Dr. John L. Lamattina, Ph.D.
Dr. John L. Lamattina, Ph.D.
Independent Director
Independent Director
31.98K
+3.93%
Mr. Andrew Reardon
Mr. Andrew Reardon
Chief Legal Officer
Chief Legal Officer
15.72K
-7.77%
Mr. Octavio (Tavo) Espinoza
Mr. Octavio (Tavo) Espinoza
Chief Financial Officer
Chief Financial Officer
10.12K
+2.26%
Dr. Nancy Ryan Gray, Ph.D.
Dr. Nancy Ryan Gray, Ph.D.
Independent Director
Independent Director
9.35K
+14.86%
Mr. Jason Haas
Mr. Jason Haas
Independent Director
Independent Director
6.86K
+21.40%
Dr. Martine Zimmermann, Pharm.D.
Dr. Martine Zimmermann, Pharm.D.
Independent Director
Independent Director
4.17K
-2.68%
Mr. Todd C. Davis
Mr. Todd C. Davis
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jason M. Aryeh
Mr. Jason M. Aryeh
Independent Director
Independent Director
127.16K
-7.29%
Dr. John W. Kozarich ,Ph.D.
Dr. John W. Kozarich ,Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
43.90K
-1.05%
Dr. Stephen L. Sabba, M.D.
Dr. Stephen L. Sabba, M.D.
Independent Director
Independent Director
35.05K
+3.57%
Dr. John L. Lamattina, Ph.D.
Dr. John L. Lamattina, Ph.D.
Independent Director
Independent Director
31.98K
+3.93%
Mr. Andrew Reardon
Mr. Andrew Reardon
Chief Legal Officer
Chief Legal Officer
15.72K
-7.77%
Mr. Octavio (Tavo) Espinoza
Mr. Octavio (Tavo) Espinoza
Chief Financial Officer
Chief Financial Officer
10.12K
+2.26%
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Oct 6
Währung: USDAktualisiert: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Kyprolis
8.80M
18.48%
Captisol
8.29M
17.40%
Filspari
6.58M
13.81%
Qarziba
5.88M
12.36%
Royalties Other
5.43M
11.41%
Andere
12.64M
26.54%
Keine Daten
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Kyprolis
8.80M
18.48%
Captisol
8.29M
17.40%
Filspari
6.58M
13.81%
Qarziba
5.88M
12.36%
Royalties Other
5.43M
11.41%
Andere
12.64M
26.54%
Aktionärsstatistik
Aktualisiert: Sun, Nov 2
Aktualisiert: Sun, Nov 2
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
13.55%
The Vanguard Group, Inc.
10.64%
Janus Henderson Investors
5.41%
Macquarie Investment Management
4.73%
State Street Investment Management (US)
3.83%
Andere
61.85%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
13.55%
The Vanguard Group, Inc.
10.64%
Janus Henderson Investors
5.41%
Macquarie Investment Management
4.73%
State Street Investment Management (US)
3.83%
Andere
61.85%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
58.05%
Investment Advisor/Hedge Fund
38.85%
Individual Investor
2.29%
Pension Fund
1.60%
Research Firm
1.26%
Bank and Trust
0.45%
Hedge Fund
0.45%
Sovereign Wealth Fund
0.10%
Venture Capital
0.04%
Institutionelle Beteiligung
Aktualisiert: Sun, Oct 5
Aktualisiert: Sun, Oct 5
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
538
19.85M
101.27%
-443.72K
2025Q2
535
19.71M
102.13%
-738.05K
2025Q1
554
19.82M
102.82%
-711.89K
2024Q4
546
19.28M
100.16%
-1.51M
2024Q3
543
19.17M
104.83%
-583.22K
2024Q2
527
18.31M
101.74%
-865.78K
2024Q1
520
17.60M
99.35%
-393.03K
2023Q4
527
16.97M
97.29%
-861.76K
2023Q3
515
17.24M
99.38%
-910.17K
2023Q2
526
17.09M
98.94%
-1.02M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
2.65M
13.55%
-19.35K
-0.72%
Jun 30, 2025
The Vanguard Group, Inc.
2.08M
10.64%
+33.19K
+1.62%
Jun 30, 2025
Janus Henderson Investors
1.06M
5.41%
+33.19K
+3.23%
Jun 30, 2025
Macquarie Investment Management
926.55K
4.73%
+20.33K
+2.24%
Jun 30, 2025
State Street Investment Management (US)
749.75K
3.83%
+22.63K
+3.11%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
704.52K
3.6%
-40.41K
-5.42%
Jun 30, 2025
Congress Asset Management Company, LLP
647.94K
3.31%
+5.23K
+0.81%
Jun 30, 2025
Chicago Capital, LLC
571.83K
2.92%
+17.31K
+3.12%
Jun 30, 2025
Stephens Investment Management Group, LLC
604.81K
3.09%
-2.41K
-0.40%
Jun 30, 2025
MFS Investment Management
339.74K
1.73%
+61.95K
+22.30%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sun, Nov 2
Aktualisiert: Sun, Nov 2
Name
Anteil
Franklin Genomic Advancements ETF
3.58%
Invesco Pharmaceuticals ETF
3%
Virtus LifeSci Biotech Products ETF
2.58%
SPDR S&P Pharmaceuticals ETF
2.56%
Invesco S&P SmallCap Health Care ETF
2.21%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.92%
Pacer US Small Cap Cash Cows Growth Leaders ETF
1.73%
Invesco Dorsey Wright Healthcare Momentum ETF
1.65%
iShares U.S. Pharmaceuticals ETF
1.28%
OneAscent Small Cap Core ETF
0.97%
Mehr Anzeigen
Franklin Genomic Advancements ETF
Anteil3.58%
Invesco Pharmaceuticals ETF
Anteil3%
Virtus LifeSci Biotech Products ETF
Anteil2.58%
SPDR S&P Pharmaceuticals ETF
Anteil2.56%
Invesco S&P SmallCap Health Care ETF
Anteil2.21%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Anteil1.92%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Anteil1.73%
Invesco Dorsey Wright Healthcare Momentum ETF
Anteil1.65%
iShares U.S. Pharmaceuticals ETF
Anteil1.28%
OneAscent Small Cap Core ETF
Anteil0.97%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
